Generic replacement of clozapine: a simple decision model from a Canadian perspective

References

• Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;250:274–85
   PubMed Web of Science ®Google Scholar
• Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997;42:139–51
   PubMed Web of Science ®Google Scholar
• Carpenter Jr. WT, Buchanan RW. Schizophrenia. New Engl J Med 1994;330:681–90
   PubMedGoogle Scholar
• Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993;16:413–23
   PubMed Web of Science ®Google Scholar
• Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509–18
   PubMed Web of Science ®Google Scholar
• De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24:519–27
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands. Schizophr Bull 1995;21:141–53
   PubMed Web of Science ®Google Scholar
• Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results, and implications. Am J Manag Care 1997;3:873–7
   PubMed Web of Science ®Google Scholar
• Kane JM. Schizophrenia. New Engl J Med 1996;334:34–41
   PubMed Web of Science ®Google Scholar
• Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11\(Suppl. 4):S397–S403
   Google Scholar
• Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safety 2000;22:195–214
   PubMed Web of Science ®Google Scholar
• Therapeutic choices, 4th ed. Ottawa: Canadian Pharmacists Association, 2003
   Google Scholar
• Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663–74
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Canada Inc. Product monograph: Clozaril®. 2003
   Google Scholar
• Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;(Suppl 17):41–5
   Google Scholar
• Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New Engl J Med 1997;337:809–15
   Google Scholar
• Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499–504
   PubMed Web of Science ®Google Scholar
• Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156:294–8
   PubMed Web of Science ®Google Scholar
• Sharif ZA, Raza A, Ratakonda SS. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. J Clin Psychiatry 2000;61:498–504
   Google Scholar
• Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46:73–7
   PubMed Web of Science ®Google Scholar
• Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998;59:585–8
   Google Scholar
• Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382–4
   PubMed Web of Science ®Google Scholar
• Flynn SW, MacEwan GW, Altman S, et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998;31:25–9
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998;59:521–7
   PubMed Web of Science ®Google Scholar
• Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med 1993;329:162–7
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630–8
   PubMed Web of Science ®Google Scholar
• Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry 1997;171:125–30
   Web of Science ®Google Scholar
• Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 2001;8:199–206
   PubMedGoogle Scholar
• Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies for orally administered drug products – general considerations. 2000. http://www.fda.gov/cder/guidance/3615fnl.pdf. [Accessed 9 Dec 2003]
   Google Scholar
• Center for Drug Evaluation and Research. Guidance: clozapine tablets: in vivo bioequivalence and in vitro dissolution testing. 1996. http://www.fda.gov/cder/guidance/clozbio.pdf. [Accessed 9 Dec 2003]
   Google Scholar
• Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994;11:1221 [Erratum11:1847]
   Google Scholar
• Lam YW, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;62(Suppl 5): 18–22
   PubMedGoogle Scholar
• Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578–92
   PubMed Web of Science ®Google Scholar
• Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001;62 (Suppl 5):14–7
   PubMedGoogle Scholar
• Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720–31
   PubMed Web of Science ®Google Scholar
• Stoner SC, Lea JW, Dubisar B, et al. A program to convert patients from trade-name to generic clozapine. Pharmacotherapy 2003;23:806–10
   PubMed Web of Science ®Google Scholar
• Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001;35:281–4
   Google Scholar
• Tse G, Thompson D, Procyshyn RM. Generic clozapine: a cost-saving alternative to brand name clozapine? Pharmacoeconomics 2003;21:1–11
   Google Scholar
• British Columbia Ministry of Health Services. Pharmacare Formulary. 2003
   Google Scholar
• Ontario Ministry of Health. Schedule of Benefits: Physician Services under the Health Insurance Act. 2000
   Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419–29
   PubMed Web of Science ®Google Scholar
• Makela EH, Cutlip WD, Stevenson JM, et al. Branded versus generic clozapine for treatment of schizophrenia. Ann Pharmacother 2003;37:350–3
   PubMed Web of Science ®Google Scholar